Gabe Sonke, MD, PhD, from the Netherlands Cancer Institute, Amsterdam, Netherlands, discusses the differences in tolerability of ribociclib in patient under 65 and over 65 at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. Patients over 65 and patients under 65 will tolerate ribociclib differently. This is because there are major differences in terms of comorbidities, concomitant medication, and physical functioning.Therefore, a subgroup analysis was carried out, showing little differences in terms of hazard ratio. There were, however, differences in side effects. For example, elderly patients were more likely to present with anaemia and fatigue. Elderly patients were also found to have a slower rate of disease progression. These factors must therefore be taken into account when determining treatment.
